Elucidation of the tumoritropic principle of hypericin

• Published in: British journal of cancer 2005-04, Vol.92 (8), p.1406-1413
• Main Authors: Van de Putte, M, Roskams, T, Vandenheede, J R, Agostinis, P, de Witte, P A M
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - pharmacokinetics; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Caco-2 Cells; Cancer Research; Carbocyanines - pharmacokinetics; Carbon Radioisotopes - pharmacokinetics; Drug Resistance; Epidemiology; Female; Humans; Lipoproteins - pharmacokinetics; Medical sciences; Mice; Microscopy, Fluorescence; Molecular Medicine; Neoplasm Transplantation; Neoplasms, Experimental - blood supply; Neoplasms, Experimental - metabolism; Neoplasms, Experimental - pathology; Oncology; Perylene - analogs & derivatives; Perylene - pharmacokinetics; Photosensitizing Agents - pharmacokinetics; Rats; Tissue Distribution; Translational Therapeutics; Tumors
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/sj.bjc.6602512

Hypericin is a potent agent in the photodynamic therapy of cancers. To better understand its tumoritropic behaviour, we evaluated the major determinants of the accumulation and dispersion of hypericin in subcutaneously growing mouse tumours. A rapid exponential decay in tumour accumulation of hypericin as a function of tumour weight was observed for each of the six tumour models investigated, and a similar relationship was found between tumour blood flow and tumour weight. Moreover, there was a close correlation between the higher hypericin uptake in RIF-1 tumours compared to R1 tumours and tumour vessel permeability. To define the role of lipoproteins in the transport of hypericin through the interstitial space, we performed a visual and quantitative analysis of the colocalisation of hypericin and DiOC 18 -labelled lipoproteins in microscopic fluorescent overlay images. A coupled dynamic behaviour was found early after injection (normalised fluorescence intensity differences were on the whole less than 10%), while a shifted pattern in localisation of hypericin and DiOC 18 was seen after 24 h, suggesting that during its migration through the tumour mass, hypericin is released from the lipoprotein complex. In conclusion, we were able to show that the tumour accumulation of hypericin is critically determined by a combination of biological (blood flow, vessel permeability) and physicochemical elements (affinity for interstitial constituents).